Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
209,618,986
-
Total 13F shares
-
194,113,234
-
Share change
-
-3,576,943
-
Total reported value
-
$1,473,202,475
-
Put/Call ratio
-
79%
-
Price per share
-
$7.59
-
Number of holders
-
281
-
Value change
-
-$36,097,738
-
Number of buys
-
128
-
Number of sells
-
146
Institutional Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q3 2025
As of 30 Sep 2025,
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) was held by
281 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
194,113,234 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock, Inc., DEERFIELD MANAGEMENT COMPANY, L.P., STATE STREET CORP, Kynam Capital Management, LP, UBS Group AG, ALKEON CAPITAL MANAGEMENT LLC, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP, MORGAN STANLEY, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
281
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.